AI Access Brief Podcast
AI Generated Daily briefings on HEOR, HTA strategy and the evidence access landscape. For pharmaceutical and biotech professionals navigating regulatory-payer alignment, HTA submissions, and evidence strategy.
AI Access Brief Podcast
DMD Access Breakthrough and CHMP Pipeline Shift
Use Left/Right to seek, Home/End to jump to start or end. Hold shift to jump forward or backward.
Welcome to Access Brief, the daily AI podcast on HEOR, HTA, and market access. I'm Marcus with Sarah. Today, NICE's third DMD approval through the Innovative Medicines Fund, CHMP's structural pipeline shift toward orphan therapeutics, and ISPOR 2026's transformative HEOR policy focus. Let's get into it.
SPEAKER_00NICE published final guidance on the 28th of May recommending Givenostat for Duchenne muscular dystrophy in ambulant patients age six and over. This makes it the third DMD treatment NICE has approved alongside Vemor alone and at Alurin. Around 530 people in England will benefit, with ITF Pharma securing funding through the Innovative Medicines Fund via a commercial agreement.
SPEAKER_01The £250,000 per year cost suggests significant commercial concessions were necessary. What's notable is how the Innovative Medicines Fund is becoming the default pathway for these ultra-rare treatments, where traditional cost-effectiveness thresholds simply don't work.
SPEAKER_00I challenge that framing, Marcus. The IMF isn't solving the fundamental tension here, site. It's just moving the commercial risk around. We now have three DMD treatments all requiring special funding arrangements. That's not sustainable pathway design, it's ad hoc problem solving.
SPEAKER_01But what's the alternative when you're dealing with progressive neuromuscular conditions in children? The clinical need is undeniable and the patient population is precisely defined. The IMF at least provides a structured framework for evidence collection alongside access.
SPEAKER_00Structured, yes, but it also signals to manufacturers that NICE's standard processes can be circumvented with the right commercial packaging. That's not exactly the incentive structure we want to embed in rare disease development.
SPEAKER_01The EMA's CHMP May meeting recommended eight new medicines for approval, including Nurandomelast for idiopathic and progressive pulmonary fibrosis, plus 13 indication extensions, but what caught my attention is the broader pipeline trend. 42% of 2025's new medicines carried orphan status.
SPEAKER_00That's a fundamental shift in development priorities. The CHMP's pipeline increasingly favors orphan designations and molecularly targeted therapies. This isn't just about scientific progress, it's about commercial strategy responding to regulatory incentives.
SPEAKER_01Exactly. And when you combine that with the pricing pressures on larger indication therapies, the economics start to make sense. Smaller, well-defined populations with high unmet need and regulatory protection.
SPEAKER_00But here's where I see a problem emerging. If nearly half of new approvals are orphan designated, we're essentially creating a two-tier system where rare disease patients get cutting-edge science while common condition patients face increasingly constrained access to innovation.
SPEAKER_01That's a fair point, but it also reflects where the genuine innovation gaps exist. Common conditions often have multiple treatment options. The real question is whether this orphan trend is clinically driven or purely commercial.
SPEAKER_00ISPER announced its 2026 Philadelphia conference concluded successfully, with program highlights emphasizing HEOR's transformative role in policy, access, and value frameworks. Their June education calendar includes multiple sessions on AI applications, JCA practical takeaways, and expanded value frameworks.
SPEAKER_01The transformative role language is interesting. It suggests HEOR is moving beyond traditional cost-effectiveness modeling into broader policy influence, but I'm curious whether that expansion brings more rigor or just more complexity.
SPEAKER_00Both probably. The JCA practical takeaway sessions suggest the field is still figuring out how to operationalize the new European landscape. And the AI applications focus shows we're layering new methodological challenges on top of existing ones.
SPEAKER_01The expanded value frameworks piece is where I see the real evolution happening, moving beyond collies toward broader societal impact measurement, though implementation remains the critical test.
SPEAKER_00Implementation and consistency. If every HTA body develops its own expanded framework, we'll have more fragmentation, not better access. The transformative potential is there, but so is the risk of making everything more complicated without improving outcomes.
SPEAKER_01Looking at this week's developments together, the DMD approval pathway complexity, the orphan designation surge, HEOR's expanding scope, we're seeing a system under significant evolutionary pressure.
SPEAKER_00The question is whether we're evolving toward better patient access or just more sophisticated ways to manage the same fundamental tensions between innovation, cost, and equity.